IL2 and neoplasm: Indeed, mouse studies conducted by Kwan et al. demonstrated that by combining a fusion protein, consisting of a mouse Fc domain and RGD-binding integrin targeting peptide, with albumin/IL-2 or anti-PD-1 immunotherapy it was possible to enhance anti-tumor immunity and tumor suppression (290).